Activity and outcomes of autologous stem cell transplantation in the private sector in Australia.
Karthik D NathYvette JamesDebra TaylorRaeina GardnerNicholas RaiRobert S WareKerry TaylorJames MortonSimon DurrantIan IrvingJohn BashfordPublished in: Internal medicine journal (2022)
We report excellent OS and low TRM, demonstrating the critical role of the private sector in the administration of this highly complex therapy. The Icon ASCT programme is the largest ASCT contributor in Queensland. It is inclusive of patients aged ≥70 years, demonstrating low and acceptable TRM.
Keyphrases
- stem cell transplantation
- end stage renal disease
- high dose
- healthcare
- health insurance
- newly diagnosed
- ejection fraction
- chronic kidney disease
- prognostic factors
- randomized controlled trial
- study protocol
- type diabetes
- stem cells
- clinical trial
- low dose
- patient reported outcomes
- adipose tissue
- mesenchymal stem cells